Another study out of Japan evaluated outcomes in a population of 1256 patients with BCBM and found there were several factors associated with improved overall survival (OS), including diagnosis of brain metastasis within 6 months of metastatic disease, asymptomatic brain metastasis, and hormone-positive or HER2-positive breast cancer [9]. This evidence concerns the gene ERBB2 and breast carcinoma.